Plain-English translation of NCT04106115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a medication that helps your immune system fight cancer, given together with a personalized cancer vaccine. The treatment combination is designed for people with a type of bladder cancer that has either stopped responding to or cannot tolerate standard therapy. Researchers want to see if this approach is safe and whether it can help keep the cancer from coming back.
Many people with this type of bladder cancer find that standard treatments stop working or cause too many side effects. This trial exists to explore whether helping the immune system recognize and attack cancer cells—using the medication plus a vaccine—might offer a better option for these patients.
You likely qualify if…
You likely don't qualify if…
Over 24 weeks, you would receive the immune medication as an IV infusion every 4 weeks (up to 7 infusions total) plus the vaccine as two injections each week for the first 6 weeks, then every other week for 9 more weeks. At week 12, you'll have a cystoscopy (a camera exam of your bladder) to check how well the treatment is working. If your cancer shows a complete response at that checkpoint, you may continue treatment; otherwise, you'll stop. You'll need regular blood tests and imaging scans throughout the trial.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United Kingdom